
United States · Startup
Biotech company developing the OS-01 peptide, which targets senescent cells and influences epigenetic markers to reverse skin aging.
United States · Startup
Biohacking skincare brand specifically formulating products with NAD+ precursors (NMN) and resveratrol to target epigenetic aging.
Consumer health company focused on aging research and supplements.
United States · Company
Supplier of liposomal NMN and NAD+ products, including transdermal serums designed to increase NAD+ levels in the skin.
Switzerland · Company
Develops Mitopure (Urolithin A), a molecule that improves mitochondrial function for both muscle performance and skin health.
France · Company
French skincare brand that partners with Harvard Medical School to develop resveratrol and honokiol-based products that activate TET enzymes and sirtuins.
United States · Company
Global beauty giant conducting extensive research into circadian rhythms, micro-RNA, and sirtuin activation (SIRT-1, SIRT-3, SIRT-6) in skin cells.
The world's first biomedical research institution exclusively dedicated to research on aging and age-related disease.
France · Company
High-end French skincare brand known for biological serums that utilize specific peptides and extracts to influence skin regeneration pathways.
Epigenetic anti-aging serums use advanced formulations containing NAD+ precursors (like nicotinamide riboside or NMN), sirtuin activators (compounds that activate longevity-associated proteins), and demethylation cofactors to influence epigenetic markers associated with skin aging. These serums target the epigenetic mechanisms that control gene expression—DNA methylation patterns, histone modifications, and chromatin structure—to potentially reverse or slow cellular aging processes. The approach is backed by omics testing (genomics, epigenomics, proteomics) and longitudinal biomarker panels that track changes in epigenetic markers, gene expression, and skin health indicators over time, enabling personalized protocols and objective measurement of intervention effectiveness.
This innovation addresses the limitation of traditional anti-aging products, which primarily address visible signs of aging without targeting underlying cellular aging mechanisms. By targeting epigenetic processes, these serums aim to achieve more fundamental improvements in skin health and appearance. Companies like various longevity-focused skincare brands, research-backed cosmetic companies, and personalized skincare platforms are exploring these approaches, with some products already incorporating NAD+ precursors and sirtuin activators.
The technology is particularly significant for the future of anti-aging skincare, where understanding and manipulating epigenetic aging could enable more effective interventions. As research progresses and compounds are validated, epigenetic serums could become a cornerstone of advanced anti-aging protocols. However, ensuring product stability, establishing clear evidence of epigenetic effects, and managing the complexity of epigenetic regulation remain challenges. The technology represents an emerging frontier in anti-aging science, but requires extensive research and validation to establish efficacy and understand long-term effects.